STOCKWATCH
·
Healthcare Research- Analytics & Technology
Quarterly Result29 Apr 2026, 08:42 pm

Indegene Q4FY26 Revenue up 32.8% YoY, crosses

AI Summary

Indegene Ltd reported strong financial results for Q4 and the full year ended March 31, 2026. In Q4 FY26, revenue grew 32.8% year-over-year to ₹10,034 million (USD 109.7 million), marking the first time quarterly revenue crossed ₹1,000 crore. Adjusted EBITDA for the quarter was ₹1,889 million, with an 18.8% margin. For the full fiscal year 2026, the company achieved a revenue of ₹35,105 million (USD 396.9 million), representing a 23.6% YoY growth. Full-year adjusted EBITDA stood at ₹6,793 million with a 19.4% margin. Cash flow from operations significantly increased by 47.3% YoY to ₹6,508 million. The Board also recommended a final dividend of ₹2.25 per equity share for FY26, a 12.5% increase from FY25. The company highlighted strong client relationships, with 53 clients contributing over $1 million in annual revenue, and breakthrough GenAI-led wins.

Key Highlights

  • Q4 FY26 revenue grew 32.8% YoY to ₹10,034 Mn, crossing ₹1,000 Cr quarterly.
  • Full-year FY26 revenue reached ₹35,105 Mn, up 23.6% YoY.
  • Adjusted EBITDA for FY26 was ₹6,793 Mn with a 19.4% margin.
  • Cash flow from operations surged 47.3% YoY to ₹6,508 Mn.
  • Board recommended a final dividend of ₹2.25 per share for FY26.
INDGN
Healthcare Research- Analytics & Technology
Indegene Ltd

Price Impact